Abemaciclib Cas 1231929-97-7
Abesilib is an oral inhibitor of cyclin-dependent kinase CDK4/6. CDK4 and CDK6 promote the phosphorylation of retinoblastomap rotein (Rb) and promote cell cycle progression and cell proliferation in HR+, HER2- breast cancer cells. Abemaciclib can inhibit the phosphorylation of Rb and block the progression of cells from G1 to S phase of the cell cycle, thus leading to cell senescence and apoptosis.
Name: Abemaciclib
Mechanism of action
Abemaciclib Cas 1231929-97-7 is a CDK4/6 inhibitor activated by binding to cyclin D. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4 and 6 can promote the phosphorylation of retinoblastoma protein (Rb), accelerating cell cycle progression and cell proliferation. In vitro, sustained exposure to abesilil inhibits Rb phosphorylation and prevents cell cycle progression from G1 to S phase, resulting in cellular senescence and apoptosis (cell death).
indications
1, It is suitable for hormone receptor positive (HR) and HER2-negative (HER2-) breast cancer that is advanced or has metastasized (spread to other parts of the body).
2. Abemaciclib Cas 1231929-97-7 can be used together with fulvestrant for women whose breast cancer disease worsens after hormone therapy.
3, It can be used alone in women and men with breast cancer whose disease has worsened after hormone therapy, and in breast cancer patients previously treated with chemotherapy for metastatic disease.
4, It is used with aromatase inhibitors as first-line hormonal therapy for breast cancer in postmenopausal women.
